SaudiBio

SAUDIBIO

THE FIRST & ONLY BIOTECHNOLOGY MANUFACTURING FACILITY IN SAUDI ARABIA

SAUDIBIO

"THE FIRST & ONLY BIOTECHNOLOGY MANUFACTURING FACILITY IN SAUDI ARABIA"

chairman new1

Working together towards drug security

Founded in 2010 by Dr.Khaled Almosa, A Health care management consultant. SAUDIBIO is a Saudi Joint Stock company duly incorporated in the Kingdom of Saudi Arabia. It is the owner of The First and Only multipurpose sterile fill and finish facility for biopharmaceutical products including Recombinant Human Insulin and Biosimilars products in Saudi Arabia.

SAUDIBIO is chaired by H.E.Dr.Hussein Aljezairy, Ex-Minister of health, Saudi Arabia and Ex-Regional director for the Eastern Mediterranean Region, World Health Organization.
Biosimilars
What we do

Utilizing advanced technologies to redefine medicine

Modular Aseptic Solutions (MAS) are utilized for fill finish of liquid solutions and lyophilization. Filling in Pre-sterilized containers is one of our primary advantage for biologicals.

As industry leaders, we are focused on a new era of development and growth powered by the Vision 2030 of Saudi Arabia

Our services

Insight into how it works when partnering with us

1

SAUDIBIO is committed to participate with government strategy towards drug security by making essential drugs locally available.

2

Localizing - Many new local regulations were issued to support and favor local products in all governmental tenders.

3

SAUDIBIO is the First & Only GMP certified biotech manufacturing facility in the Kingdom of Saudi Arabia

4

Our capabilities in the region - beyond manufacturing- include registration of products at regulatory authorities and generating ethical sales across MENA.

Our Business Partners

Strength through our unique diversity

NOVO NORDISK is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.

NOVO NORDISK and SAUDIBIO have signed license, supply and quality agreements for local manufacturing of Insulin and Haemophilia products.

SANDOZ is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group.

SANDOZ & SAUDIBIO have signed license, supply and quality agreements for local manufacturing of selected biosimilars.

GLENMARK is a leading integrated research-based, global pharmaceutical company and it is the first company in India has received approval from DCGI to manufacture & market an oral antiviral drug Fabiflu (Favipiravir) for use in mild to moderate COVID-19 .

GLENMARK and SAUDIBIO have signed license, supply and quality agreements of selected branded generics including favipiravir.

vision2030

Benefiting the community - locally and globally

We adopt the highest quality standards to deliver reliable service & high-quality products from the GMP Certified production facility.
We care for the community we live and work in.

vision2030
supporters

Interested in finding out more? Get in touch.

Keep in touch

Fill in your details and we’ll get back to you in no time.